NR1D1 and breast cancer: SR9009 also demonstrated similar antiproliferative effects in bladder cancer (BC); downregulated NR1D1 was associated with poor prognosis, and REV-ERB activation suppressed the invasion of BC cells in in vitro models (cell lines: RT4, T-24 and 5637) [42].